Guilford v. Boston Scientific Corporation

CourtDistrict Court, W.D. Missouri
DecidedApril 3, 2020
Docket4:19-cv-00955
StatusUnknown

This text of Guilford v. Boston Scientific Corporation (Guilford v. Boston Scientific Corporation) is published on Counsel Stack Legal Research, covering District Court, W.D. Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Guilford v. Boston Scientific Corporation, (W.D. Mo. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF MISSOURI WESTERN DIVISION

DONNA GUILFORD, ) ) Plaintiff, ) ) v. ) No. 4:19-CV-00955-DGK ) BOSTON SCIENTIFIC CORPORATION, ) ) Defendant. )

ORDER GRANTING IN PART DEFENDANT’S MOTION TO DISMISS

This products-liability action arises out of Plaintiff Donna Guilford’s injuries after being implanted with two of Defendant Boston Scientific Corporation’s surgical-mesh products, Pinnacle Pelvic Floor Repair Kit (the “Pinnacle”) and Obtryx Mid-Urethral Sling (the “Obtryx Sling” and collectively with the Pinnacle, the “Products”). Now before the Court is Defendant’s motion to dismiss (Doc. 9). For the reasons below, the motion is GRANTED IN PART. Background For purposes of resolving the pending motion, the relevant allegations in Plaintiff’s complaint are summarized as follows. In the late 2000s, Plaintiff suffered from cystocele and stress urinary incontinence. To treat those conditions, Dr. Willis Kephart at Lafayette Regional Heath Center in Lexington, Missouri, surgically implanted Plaintiff with the Pinnacle and the Obtryx Sling in 2009. The Products are both surgical-mesh devices containing monofilament polypropylene mesh that are manufactured, packaged, labeled, marketed, sold, and distributed by Defendant as treatments for stress urinary incontinence and cystocele. In the years after being implanted, Plaintiff began experiencing pain and had the Products removed in 2018. She alleges she has sustained injuries to the pelvic-region and deformities that will require future corrective surgeries. Plaintiff brought this lawsuit in November 2019, alleging seven causes of action: (1) negligence; (2) strict liability—design defect; (3) strict liability—manufacturing defect; (4) strict liability—failure to warn; (5) breach of warranty; (6) gross negligence; and (7) punitive damages. Defendant then filed the instant motion to dismiss, alleging that all Plaintiff’s claims should be dismissed because they allege only conclusory facts that do not satisfy federal pleading standards.

Standard of Review Because this Court has diversity jurisdiction over this matter, state law governs substantive issues, but federal law governs procedure. Paine v. Jefferson Nat’l Life Ins. Co., 594 F.3d 989, 991– 92 (8th Cir. 2010). Under Federal Rule of Civil Procedure 12(b)(6), a court may dismiss a complaint if it fails “to state a claim upon which relief can be granted.” To avoid dismissal, a complaint must include “enough facts to state a claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). In reviewing the complaint, the court construes it liberally and draws all reasonable inferences from the facts in the plaintiff’s favor. Monson v. Drug Enforcement Admin., 589 F.3d 952, 961 (8th Cir. 2009).

Discussion I. Plaintiff has stated a negligence claim. “In any action for negligence, a plaintiff must establish the defendant owed a duty of care to the plaintiff, the defendant breached that duty, and the defendant’s breach proximately caused the plaintiff’s injury.” Wieland v. Owner-Operator Servs., Inc., 540 S.W.3d 845, 848 (Mo. banc 2018) (citation omitted). “[M]edical device manufacturers have ‘the duty to exercise ordinary and reasonable care not to expose the potential consumer to an unreasonable risk of harm from the use of its products.’” Mack v. Stryker Corp., 748 F.3d 845, 849 (8th Cir. 2014) (quoting O’Hare v. Merck & Co., 381 F.2d 286, 291 (8th Cir. 1967)). Plaintiff’s complaint alleges that Defendant represented its pelvic-mesh products, including those used on Plaintiff, were safe. Compl. at ¶ 39. But Plaintiff lists sixteen ways that Defendant’s Products were not prudently designed and manufactured, including that it used polypropylene material—a “material that is biologically incompatible with human tissue” —and non-medical grade, counterfeit material illegally smuggled in from China to make the Products. Id. at ¶ 32. Defendants

had a duty to all foreseeable plaintiffs to ensure the safety of its products. Id. at ¶ 27. Instead of so doing, Plaintiff alleges Defendant failed to adequately study the risks or knew that such risks could cause serious injuries to patients receiving the devices but ignored those risks in constructing its Products and marketing its Products as safe and effective, thereby breaching its duty of care to Plaintiff. Id. at ¶¶ 34–35, 40–41. Plaintiff’s physician relied on Defendant’s false representations about the efficacy of the Products when opting to use them on Plaintiff, and but for those representations, Plaintiff would not have consented to the implantation of the Products. Id. at ¶ 42– 44. The Products injured Plaintiff. Id. at ¶ 40. Thus, Plaintiff factually establishes the elements of a negligence claim that is plausible on its face, and so her negligence claim remains.

II. Plaintiff has stated a claim for failure to warn her physician. Next, Defendant claims that, under Missouri’s learned-intermediary doctrine, Plaintiff has failed to state a claim for failure to warn under the strict-liability and negligence theories to the extent such claims rely on a duty to warn anyone other than Plaintiff’s physician. This point is well-taken. The elements of strict tort liability are fulfilled “if the product was in an unreasonably dangerous defective condition when put to a reasonably anticipated use, and the plaintiff was damaged as a direct result of such defective condition as existed when the product was sold.” Smith v. Brown & Williamson Tobacco Corp., 275 S.W.3d 748, 791 (Mo. Ct. App. 2008) (emphasis omitted); Mo. Rev. Stat. § 537.760. A plaintiff may prove that a product is unreasonably dangerous due to an inadequate or nonexistent warning. Nesselrode v. Executive Beechcraft, Inc., 707 S.W.2d 371, 375, 384 (Mo. banc 1986). The key issue in a failure-to-warn case is whether the information included with the product “effectively communicates to the consumer or user the dangers that inhere in the product during normal use and the dangerous consequences that can or will result from misuse or abnormal use of the product.” Id. at 382.

But under the learned-intermediary doctrine, a medical-device manufacturer satisfies its duty to warn by providing adequate warnings to the prescribing physician. Mitchell v. Covidien Plc, No. 4:14-CV-0636-FJG, 2015 WL 12804270, at *5 (W.D. Mo. Sept. 28, 2015) (citing Kirsch v. Picker Int’l, Inc., 753 F.2d 670. 671 (8th Cir. 1985)). Thus, to plead a viable failure-to-warn claim in a prescription-medical-device case in Missouri, the plaintiff must allege facts showing: “(1) that the defendant failed to warn the prescribing physician of a risk associated with the use of the product . . . and (2) that the failure to warn the physician was both a cause in fact and the proximate cause of the plaintiff[s’] injury.” Brinkley v. Pfizer, Inc.,

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Elisabeth Kirsch v. Picker International, Inc.
753 F.2d 670 (Eighth Circuit, 1985)
Monson v. Drug Enforcement Administration
589 F.3d 952 (Eighth Circuit, 2009)
Paine v. Jefferson National Life Insurance
594 F.3d 989 (Eighth Circuit, 2010)
Pritchett v. Cottrell, Inc.
512 F.3d 1057 (Eighth Circuit, 2008)
Smith v. Brown & Williamson Tobacco Corp.
275 S.W.3d 748 (Missouri Court of Appeals, 2008)
Witherspoon v. General Motors Corp.
535 F. Supp. 432 (W.D. Missouri, 1982)
Renaissance Leasing, LLC v. Vermeer Manufacturing Co.
322 S.W.3d 112 (Supreme Court of Missouri, 2010)
Richcreek v. General Motors Corp.
908 S.W.2d 772 (Missouri Court of Appeals, 1995)
Matulunas v. Baker
569 S.W.2d 791 (Missouri Court of Appeals, 1978)
Nesselrode v. Executive Beechcraft, Inc.
707 S.W.2d 371 (Supreme Court of Missouri, 1986)
Keener v. Dayton Electric Manufacturing Company
445 S.W.2d 362 (Supreme Court of Missouri, 1969)
Carol Mack v. Stryker Corporation
748 F.3d 845 (Eighth Circuit, 2014)
Shirley Brinkley v. Pliva, Inc.
772 F.3d 1133 (Eighth Circuit, 2014)
Wieland v. Owner-Operator Servs., Inc.
540 S.W.3d 845 (Supreme Court of Missouri, 2018)
Harris v. Jungerman
560 S.W.3d 549 (Missouri Court of Appeals, 2018)
Willett v. Baxter International, Inc.
929 F.2d 1094 (Fifth Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Guilford v. Boston Scientific Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/guilford-v-boston-scientific-corporation-mowd-2020.